The Pharmacokinetic and Pharmacodynamic Effects of Varying the Free Fraction of Disopyramide
- The Clinical Scope of Disopyramide Seven Years After Introduction -- An Overview. Willis III, Park W. // Angiology;Feb1987 Part 2, Vol. 38, p165
Disopyramide phosphate, seven years after its introduction, has proved to be a useful and effective Type IA oral agent for treatment of ventricular arrhythmias. The experience of these seven years has amplified and more sharply defined the initial efficiency and safety issues related to the use...
- A Review of the Effects of Disopyramide Phosphate on Left Ventricular Function and the Peripheral Circulation. Di Bianco, Robert; Gottdiener, John S.; Singh, Steven N.; Fletcher, Ross D. // Angiology;Feb1987 Part 2, Vol. 38, p174
In the absence of preexistent myocardial dysfunction, the risk of producing cardiac decompensation in patients being treated with any of the conventional antiarrhythmic agents is low. The availability of disopyramide for clinical use in 1977 produced optimism for an effective antiarrhythmic...
- Pharmacologic Evaluation of Standard and Controlled-Release Disopyramide. Siddoway, Lyle A.; Barbey, J. Toby; Roden, Dan M.; Woosley, Raymond L. // Angiology;Feb1987 Part 2, Vol. 38, p184
Controlled-release disopyramide offers many potential advantages over the standard formulation for improved patient compliance, possible reduction of concentration-related adverse effects, and predictability of pharmacologic effect. The pharmacology of disopyramide, potential advantages and...
- Long-Term Use of Controlled-Release Disopyramide in Patients with Severe Ventricular Arrhythmias. Paulk Jr., E. Alan // Angiology;Feb1987 Part 2, Vol. 38, p198
Controlled-release (CR) disopyramide phosphate has been available for the past four years for the management of patients with ventricular arrhythmias. The advantages of this preparation over the earlier form have for most patients been striking Improved patient compliance as regards dosing, ease...
- Transfer from Immediate-Release Disopyramide to Controlled-Release Disopyramide. DiPersio, David M.; Chow, Moses S. S. // Angiology;Feb1987 Part 2, Vol. 38, p188
Simulation of serum disopyramide concentrations during transfer from steady-state immediate-release (IR) disopyramide to a sustained-release disopyramide preparation was performed based on pharmacokinetic parameters obtained from fit disopyramide and serum concentrations measured following an...
- Enantioselective binding of disopyramide to Î±1-acid glycoprotein and its variants. Kishino, S.; Itoh, S.; Nakagawa, T.; Miyazaki, K. // European Journal of Clinical Pharmacology;Oct2001, Vol. 57 Issue 8, p583
Objective: Î±1-Acid glycoprotein (AAG) has three main genetic variants, F1, S, and A variants. There are few reports on the correlation between AAG variants and binding activity of drug enantiomers. We studied the differences between the binding characteristics of enantiomers of disopyramide...
- Rythmodan Retard. // Royal Society of Medicine: Medicines;2002, p483
The article presents information on rhythmodan retard, a proprietary, prescription-only preparation of the anti-arrhythmic disopyramide. It is available as modified-release tablets.
- disopyramide. // Davis's Drug Guide for Nurses, 9th edition;2005, p322
Provides clinical information on the antiarrhythmic drug disopyramide. Indications for the drug; Mechanism of action; Contraindications and precautions; Adverse reactions and side effects.
- propranolol. // Davis's Drug Guide for Nurses, 9th edition;2005, p891
Presents information on the antianginal, antiarrhythmic, antihypertensive and vascular headache suppressant, propranolol. Indications; Pharmacokinetics; Adverse reactions and side effects.